In the clinical setting, Vav3 is associated with cancer progression and recurrence (Lin et al. 2012) and furthermore mediates resistance to certain treatments, such as breast cancer endocrine therapy (Aguilar et al. 2014). This evidence concerns the gene VAV3 and cancer.